ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
GREENWOOD VILLAGE, Colo. & LOS ANGELES -- Businesswire -- ANANDA Scientific Inc., (a biotech pharma company) today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. The study will be done at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA.
“This is the fourth IND approval for our investigational drug Nantheia™ product line, and it further re-enforces our vision of developing CBD as a therapeutic for a number of key indications. This clinical study at UCLA is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need,” said Sohail R. Zaidi, ANANDA’s Chief Executive Officer. “We are excited to be working with the UCLA team and look forward to this trial advancing.”
This trial is being led by principal investigators Edythe London, Ph.D., Distinguished Professor of Psychiatry and Biobehavioral Sciences as well as Molecular and Medicinal Pharmacology at the Jane and Terry Semel Institute at David Geffen School of Medicine UCLA, and Richard De La Garza II, Ph.D., Professor of Psychiatry and Biobehavioral Sciences at the Jane and Terry Semel Institute at David Geffen School of Medicine UCLA. Funding for this trial is from the National Institute on Drug Abuse (NIDA). (Clinical Trials.gov Identifier: NCT03787628)
“The approval of the IND for this important clinical trial is a key milestone for our ongoing research into therapeutic alternatives for opioid use disorder and reversal of the effects of the opioid epidemic,” said Dr. London.
“With the IND approved we are now moving quickly to get the trial under way,” said Dr. De La Garza.
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biotech company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder. The company employs patented delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd. Jerusalem, Israel) to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality pharmaceutical products. Consistent with its strong research-based data, the company also has a growing pipeline of nutraceutical over-the-counter products. The company has successfully launched these products in the US, Australia, and the UK, with expansion into additional markets such as the EU, China, Africa, and other countries in Asia. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its technology portfolio.
Photos/Multimedia Gallery Available: https://www.businesswire.com/news/home/52556661/en
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:ANANDA Scientific Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 김명중 사진작가와 프로쉬 ‘22세기 유물전’ 개최 - 뉴스와이어
- 송도국제캠핑장, 바베큐장 ‘더 팜 송도’ 그랜드 오픈 - 뉴스와이어
- ‘역대 최대 115만여 명 참가’ 제21회 서울국제환경영화제 성공적 마무리 - 뉴스와이어
- 벼룩시장 조사, 직장인 10명 중 9명 ‘고용불안 느낀다’ - 뉴스와이어
- HL만도 주차로봇 ‘파키’ 인천국제공항서 발렛파킹 실증 운영 - 뉴스와이어
- AI 버추얼 아티스트 수비, 디지털 싱글 ‘SUNCREAM’ 콘셉트 포토 공개 - 뉴스와이어
- 반스 월드 2, 로블록스에서 새로운 스케이트 챌린지 선보여 - 뉴스와이어
- 영진약품, Dx&Vx와 전략적 MOU 체결… 혁신신약 포트폴리오 강화 나서 - 뉴스와이어
- 증가하는 청년 자살… 청년이 직접 자살예방 활동을 하는 ‘청년 자살예방 서포터즈 3기’ 출발
- 소셜 브랜드 제리백 ‘10주년 생일카페’ 성수팝업 진행 - 뉴스와이어